https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.6_suppl.107
Clinical outcomes of abiraterone acetate (AA) or enzalutamide (E) as first-line therapy (Rx) for men aged ≥75 with metastatic castration-resistant prostate cancer (mCRPC) according to previous use of docetaxel (D) for metastatic castration-sensitive prostate cancer (mCSPC) in a multicenter international registry: A SPARTACUSS – Meet-URO 26 study / Lee-Ying, Richard M.; Saieva, Calogero; Nuzzo, Pier Vitale; Malgeri, Andrea; Fotia, Giuseppe; Zanardi, Elisa; Rossetti, Sabrina; Valenca, Loana Bueno; Patrikidou, Anna; Modesti, Mikol; Martins Oliveira, Thiago; Pignata, Sandro; Fornarini, Giuseppe; Procopio, Giuseppe; Santini, Daniele; Sweeney, Christopher; Heng, Daniel Yick Chin; De Giorgi, Ugo; Russo, Antonio; Francini, Edoardo. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - ELETTRONICO. - 41:(2023), pp. 107-107. [10.1200/JCO.2023.41.6_suppl.107]
Clinical outcomes of abiraterone acetate (AA) or enzalutamide (E) as first-line therapy (Rx) for men aged ≥75 with metastatic castration-resistant prostate cancer (mCRPC) according to previous use of docetaxel (D) for metastatic castration-sensitive prostate cancer (mCSPC) in a multicenter international registry: A SPARTACUSS – Meet-URO 26 study
Modesti, Mikol;Francini, Edoardo
Conceptualization
2023
Abstract
https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.6_suppl.107
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
